21.9 C
Monday, September 27, 2021

J&J reports promising Ebola vaccine data

The two-dose routine was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98% of all members, the corporate mentioned, citing data from a late-stage trial.

The routine, Ad26.ZEBOV and MVA-BN-Filo, generated immune responses that endured in adults for not less than two years. J&J added that there have been no security alerts of concern.

“These peer-reviewed data support the prophylactic use of the Johnson & Johnson Ebola vaccine regimen to protect people at risk of Ebola, which is essential to our vision of preventing Ebola outbreaks before they can begin,” J&J’s Chief Scientific Officer Paul Stoffels mentioned.

The firm added {that a} booster shot administered two years after the preliminary vaccination induced a powerful immune response inside seven days.

Ebola usually kills about half of these it infects, though vaccines and new remedies have confirmed extremely efficient in decreasing fatality charges.

Last month, the World Health Organisation warned that on prime of the COVID-19 pandemic, West Africa is going through new outbreaks of the viral haemorrhagic fevers Marburg and Ebola, risking large strains on ill-equipped well being techniques.

J&J’s vaccine routine had acquired European approval in July 2020 and prequalification from the WHO, which permits medicines to be procured by creating international locations, in April 2021.

#Note-Author Name –

Related Articles


Please enter your comment!
Please enter your name here

Stay Connected

- Advertisement -spot_img

Latest Articles